Invention Grant
- Patent Title: Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof
-
Application No.: US16872140Application Date: 2020-05-11
-
Publication No.: US11512137B2Publication Date: 2022-11-29
- Inventor: Simone Oostindie , Frank Beurskens , Esther Breij , Edward Van Den Brink , Andreas Hollenstein , Marije Overdijk , Margaret Lindorfer , Ronald Taylor , Paul Parren , Hilma Van Der Horst , Martine E. D. Chamuleau , Tuna Mutis
- Applicant: GENMAB HOLDING B.V.
- Applicant Address: NL Utrecht
- Assignee: GENMAB HOLDING B.V.
- Current Assignee: GENMAB HOLDING B.V.
- Current Assignee Address: NL Utrecht
- Agency: Nelson Mullins Riley & Scarborough LLP
- Agent Jane E. Remillard, Esq.; Christopher L. Frank
- Priority: WOPCT/EP2018/057836 20180327
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61P35/00 ; A61K49/00 ; G01N33/68 ; A61K39/00
Abstract:
CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
Public/Granted literature
- US20200291124A1 BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF Public/Granted day:2020-09-17
Information query
